Subscribe To
IMRN / Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
IMRN News
By GlobeNewsWire
September 11, 2023
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biophar more_horizontal
By Market Watch
May 8, 2023
Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment
The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmace more_horizontal
By Proactive Investors
March 6, 2023
Immuron CEO highlights strong sales growth in business update presentation
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore highlighted the strong growth in sales of oral immunotherapeutic products in the company's Fe more_horizontal
By Seeking Alpha
September 6, 2022
Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript
Immuron Limited (NASDAQ:IMRN ) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive O more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal